Plain-English translation of NCT05648591 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a safety study testing , a medication used to treat schizophrenia and bipolar I disorder, in teenagers ages 12 to 17. Researchers want to see how well the medication is tolerated and what side effects young people experience when taking it for up to one year. This medication has been used in adults, and this study helps doctors understand if and how it works safely in teenagers.
While this medication is approved for adults with these conditions, there is limited safety information in teenagers. This study fills that gap so doctors can make better decisions about treating young people with schizophrenia or bipolar I disorder.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily, with doses that may be adjusted between 8 and 24 mg per day based on how you respond and tolerate it. You would visit the clinic regularly over 52 weeks (one year) for the research team to monitor your health, check for side effects, and answer questions about how you're feeling. Throughout the study, you and your parent or guardian would work closely with the research doctors to ensure the treatment is working safely for you.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States